Print

pSivida Corp (PSDV) Announces UK's National Institute for Clinical Excellence (NICE) Says Yes to ILUVIEN® in Some Patients With Diabetic Macular Edema in New Draft Guidance  
6/14/2013 10:26:05 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV - News), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that the United Kingdom’s National Institute for Health and Care Excellence (NICE) issued draft guidance recommending ILUVIEN® for the treatment of pseudophakic patients (those who have undergone prior cataract surgery) with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. Following a rapid review by NICE, this recommendation proposes a change to the published guidance issued by NICE in January 2013 and takes into consideration a patient access scheme (PAS) submitted by Alimera.

Help employers find you! Check out all the jobs and post your resume.

//-->